

INFORMAZIONI PERSONALI

Schepisi Giuseppe✉ giuseppe.schepisi@irst.emr.it

Sesso Maschile | Nazionalità Italiana

POSIZIONE RICOPERTA

Medico Oncologo

ISTRUZIONE E FORMAZIONE

30 GIU. 14 **Specializzazione in Oncologia Medica (Voto finale 50/50 con lode).
Tesi su: "Stato dell'arte nel trattamento del melanoma cutaneo"**

Università degli Studi di Messina - AOU "G. Martino"
Via Consolare Valeria, 98125 Messina (Italia)

Attività professionali, scientifiche e tecniche

18 LUG. 07 **Abilitazione alla professione di Medico Chirurgo (Votazione finale
266/270)**

Università degli Studi di Messina - AOU "G. Martino"
Via Consolare Valeria, 98125 Messina (Italia)

Attività professionali, scientifiche e tecniche

22 MAR. 07 **Laurea in Medicina e Chirurgia (Voto di Laurea 110/110 con lode);
Tesi su: "Terapia antiangiogenetica nel tumore del polmone non a
piccole cellule"**

Università degli Studi di Messina - AOU "G. Martino"
Via Consolare Valeria, 98125 Messina (Italia)

Attività professionali, scientifiche e tecniche

LUG. 00 **Diploma di maturità Classica (Voto 100/100)**

Liceo Classico "G. La Farina"
Via Oratorio della Pace, 98122 Messina (Italia)

ESPERIENZA
PROFESSIONALE

1 AGO. 17 – ALLA DATA
ATTUALE **Medico Oncologo - Incarico a Tempo Indeterminato presso IRCCS - IRST -
Gruppo di patologia Uro-ginecologico.**

IRCCS - IRST (Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"), Meldola (Forlì-Cesena)
(Italia)

Attività professionale svolta presso Day Hospital, Ambulatori, Degenza IRST

Attività scientifica: conduzione di studi clinici in qualità di sub-investigatore, produzione di articoli scientifici,
partecipazione ad Investigator Meetings

1 SET. 2016 – 31 LUG. 2017 **Medico Oncologo - Incarico a Tempo Determinato presso IRCCS - IRST - Gruppo
di patologia Uro-ginecologico.**

IRCCS - IRST (Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"), Meldola (Forlì-Cesena)
(Italia)

Attività professionale svolta presso Day Hospital, Ambulatori, Degenza IRST

Attività scientifica: conduzione di studi clinici in qualità di sub-investigatore, produzione di articoli scientifici,
partecipazione ad Investigator Meetings

- 1 DIC. 14 – 31 AGO. 2016 **Medico Oncologo - Contratto Libero Professionale presso IRCCS - IRST - Gruppo di patologia Uro-ginecologico.**
IRCCS - IRST (Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"), Meldola (Forlì-Cesena) (Italia)
Attività professionale svolta presso Day Hospital, Ambulatori, Degenza IRST
Attività scientifica: conduzione di studi clinici in qualità di sub-investigatore, produzione di articoli scientifici, partecipazione ad Investigator Meetings
- 1 SET. 14 – 30 NOV. 14 **Medico Oncologo - Tirocinio Volontario presso IRCCS – IRST - Reparto di Oncologia**
IRCCS – IRST (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Meldola (Forlì-Cesena) (Italia)
Attività professionale svolta presso Degenza IRST
- OTT. 12 – GIU. 14 **Tirocinio Professionalizzante presso Day Hospital Oncologico, nell'ambito del Corso di Specializzazione in Oncologia Medica**
AOU G. Martino, Messina (Italia)
[Attività o settore](#) Attività professionali, scientifiche e tecniche
- MAR. 12–OTT. 12 **Tirocinio Professionalizzante presso Hospice Oncologico, nell'ambito del Corso di Specializzazione in Oncologia Medica**
AOU G. Martino, Messina (Italia)
[Attività o settore](#) Attività professionali, scientifiche e tecniche
- OTT. 11 – MAR. 12 **Tirocinio Professionalizzante presso Day Hospital Oncologico, nell'ambito del Corso di Specializzazione in Oncologia Medica**
AOU G. Martino, Messina (Italia)
[Attività o settore](#) Attività professionali, scientifiche e tecniche
- GIU. 10 – OTT. 11 **Tirocinio Professionalizzante presso Reparto di Oncologia, nell'ambito del Corso di Specializzazione in Oncologia Medica**
AOU G. Martino, Messina (Italia)
[Attività o settore](#) Attività professionali, scientifiche e tecniche
- 30 NOV. 09 – 26 GIU. 10 **Tirocinio professionalizzante presso i reparti di Geriatria e Medicina delle Malattie Metaboliche, nell'ambito del Corso di Specializzazione in Oncologia Medica**
AOU G. Martino, Messina (Italia)
[Attività o settore](#) Attività professionali, scientifiche e tecniche
- GIU. 09 – NOV. 09 **Tirocinio professionalizzante presso il Reparto di Oncologia, nell'ambito del Corso di Specializzazione in Oncologia Medica**
AOU G. Martino, Messina (Italia)
[Attività o settore](#) Attività professionali, scientifiche e tecniche

COMPETENZE PERSONALI

LINGUA MADRE **italiano**

ALTRE LINGUE

	COMPRENSIONE		PARLATO		PRODUZIONE SCRITTA
	ASCOLTO	LETTURA	INTERAZIONE	PRODUZIONE ORALE	
francese	C1	C1	B2	B2	B2
inglese	B1	B1	B1	B1	B1
spagnolo	B1	B1	A2	A2	A2
greco moderno	A1	A1	A1	A1	A1
russo	A1	A1	A1	A1	A1

Livelli: A1 e A2: Utente base - B1 e B2: Utente autonomo - C1 e C2: Utente avanzato

Quadro Comune Europeo di Riferimento delle Lingue

COMPETENZE COMUNICATIVE

Capacità di lavorare in gruppo maturata in molteplici situazioni in cui era indispensabile la collaborazione tra figure diverse e con modalità orarie varie (turni, fine settimana)

COMPETENZE ORGANIZZATIVE E GESTIONALI

- Capacità di lavorare in situazioni di stress, legate soprattutto al rapporto con il pubblico e alle scadenze delle attività lavorative

- Capacità di adattamento a diversi contesti lavorativi, acquisita durante le mie esperienze professionali in differenti reparti

COMPETENZE PROFESSIONALI

- **Partecipazione a ricerche scientifiche e promozione e diffusione di programmi di ricerca scientifica**
 - o Partecipazione ad oltre 160 studi clinici internazionali, condotti in qualità di Sub-Investigator e altri in qualità di Principal Investigator Locale: tra questi ultimi, 1 (ARAMIS trial) con successiva pubblicazione su New England Journal of Medicine fra gli ARAMIS Investigators (vedi appendice 2)
 - o Partecipazione ai seguenti studi IRST condotti in ambito multidisciplinare con Laboratorio IRST, in qualità di Sub-Investigator e con gestione dei pazienti presso l'ambulatorio dedicato alle Terapie Sperimentali:
 - IRST 100.49 "Hormone therapy and COVID-19 infection in cancer patients"
 - IRST B030 "Circulating Tumor Cells, free DNA, Stem Cells and EMT-related antigens as biomarkers of activity of cabazitaxel in castration-resistant prostate cancer: a proof of concept"
 - IRST B048 "Biomarkers Predicting Outcome in Patients with Advanced castration-refractory prostate cancer (CRPC) Treated With Enzalutamide and Abiraterone"
 - IRST B073 "Biomarker Study: The next generation of prostate cancer biomarkers"
 - IRST B074 "Next generation biomarkers for urothelial cancer"
 - IRST B092 "Biomarcatori di nuova generazione nel carcinoma renale"
 - PRIME "Sviluppo del test PRIME per l'identificazione di biomarcatori tramite biopsia liquida (non invasiva) in pazienti con tumore alla prostata." Quest'ultimo in collaborazione con Oncologia di Trento
 - IRST B144 – IGG04 "Studio sui biomarcatori: i biomarcatori di prossima generazione nei tumori a cellule germinali"
 - o Co-referente in Attività di ambulatorio dedicato alla gestione Studi Sperimentali dal 2015 ad oggi
 - o Medico inserito nell'Organigramma degli studi di Fase 1 (Settore Uroginecologico)

presso IRCCS IRST di Meldola dal 15 Luglio 2016

- Partecipazione ad Advisor Board:
 - Advisory Board organizzato da Doxa Pharma S.r.l. dal titolo: “Carcinoma del rene in fase avanzata” tenutosi a Bologna il 19 Maggio 2022
 - Advisory Board organizzato da Bayer dal Titolo: “Nuovi scenari e sequenza di trattamento nel tumore della prostata metastatico: -mHSPC: ARASENS come Practice changes? -mCRPC: Radium 223 nella pratica clinica e nel trial RAPSON”, tenutosi da remoto il 6 Luglio 2022
 - Advisory Board organizzato da Medical Net S.r.l. dal titolo: “Carcinoma della prostata mHSPC: confronto su innovazione e sequenze di trattamento” tenutosi a Bologna l’08 Novembre 2024
- Attività di revisore di progetti scientifici per conto di Istituzioni Scientifiche di Paesi Esteri
 - Revisore di 1 Grant Application per conto del Cancer Research Trust NZ, il secondo più grande ente di beneficenza dedicato alla ricerca sul cancro della Nuova Zelanda (cancerresearchtrustnz.org.nz) a Maggio 2021
 - Revisore di 1 Grant Application al Tyrolean Science Fund (programma di finanziamento locale per giovani ricercatori in Tirolo) per conto dell’Università di Innsbruck (Austria) a Luglio 2022
 - Revisore di 1 Grant Application al KWF Kankerbestrijding – Dutch Cancer Society (DCS) – Amsterdam (Paesi Bassi) a Febbraio 2024
- Esperienze di studio e ricerca
 - Partecipazione ad oltre 160 studi clinici internazionali, condotti in qualità di Sub-Investigator e 1 (ARAMIS trial) condotto in qualità di Principal Investigator locale con successiva pubblicazione su New England Journal of Medicine fra gli ARAMIS Investigators (vedi appendice 2)
 - Partecipazione n°7 studi IRST condotti in ambito multidisciplinare con Laboratorio IRST, in qualità di Sub-Investigator e con gestione dei pazienti presso l’ambulatorio dedicato alle Terapie Sperimentali (lista vedi sopra)
 - Attività di ambulatorio dedicato alla gestione dei pazienti in Studi Sperimentali dal 2015 ad oggi
 - Partecipazione, in qualità di Sub-investigator, allo studio BIO-TEST, risultato vincitore di un finanziamento complessivo pari ad 1 milione di euro dal Piano Nazionale di Ripresa e Resilienza (Bando PNNR) attraverso la call del 2023 "Malattie rare: sviluppo di soluzioni trasversali che possano avere impatto su molteplici patologie in termini di ricerca e assistenza" (PI: Ugo De Giorgi).
- Partecipazione a stage e attività pubblicistica:
 - Attività pubblicistica, prevalentemente rivolta ai tumori Genitourinari, con particolare riguardo all’ambito delle Terapie Innovative
 - Pubblicazioni: In totale 75 articoli su pubmed su tumori genitourinari e/o terapie innovative (tot Impact factor). (vedi sotto “Pubblicazioni in extenso”)
 - H-index e citazioni: (Scopus h index: 21; Google Scholar h index: 24; i10-index: 49; N° citazioni 1734 alla data del 24/02/2026)
 - Primo nome in 14 articoli tra cui
 - Lancet Oncol [IF 2015 = 26.509]
 - Jama Int Med [IF 2017 = 19.989]
 - J Immunother Cancer [IF 2019 = 9.913]
 - Secondo o ultimo nome in ulteriori 6 articoli tra cui
 - Cancers [IF 2021 = 6.32]
 - Coautore in 2 articoli pubblicati su
 - ◆ New Eng J Med [IF 2019 = 70.6]
 - ◆ J Clin Oncol [IF 2025 = 41.9]
 - Attività di revisore di articoli scientifici per conto delle seguenti riviste scientifiche internazionali con oltre 20 revisioni all’anno eseguite mediamente:

- 1. Annals of Palliative Medicine
- 2. Applied Sciences
- 3. Archivum Immunologiae et Therapiae Experimentalis
- 4. Asian Journal of Urology
- 5. Basic and Clinical Andrology
- 6. Biocell
- 7. Biochemical and Biophysical Research Communications
- 8. Biochemistry and Biophysics Reports
- 9. Biomarker Insights
- 10. Biomedicines
- 11. Bladder
- 12. BMC Urology
- 13. Canadian Journal of Urology
- 14. Cancer Cell International
- 15. Cancer Epidemiology
- 16. Cancer Gene Therapy
- 17. Cancer Letters
- 18. Cancer Management and Research
- 19. Cancer Reports
- 20. Cancer Treatment and Research Communications
- 21. Cancers
- 22. Case Reports in Oncological Medicine
- 23. Cellular & Molecular Biology Letters
- 24. Clinical and Experimental Medicine
- 25. Clinical Epidemiology
- 26. Current Issues in Molecular Biology
- 27. Current Oncology
- 28. Diagnostics
- 29. Discover Oncology
- 30. Diseases
- 31. Drug Design, Development and Therapy
- 32. eBio Medicine
- 33. Ecancer Medical Science
- 34. Eurasian Journal of Medicine and Oncology
- 35. European Urology
- 36. Expert Opinion on Biological Therapy
- 37. Expert Review of Anticancer Therapy
- 38. Expert Review of Clinical Pharmacology
- 39. Frontiers in Bioscience-Landmark
- 40. Frontiers in Endocrinology
- 41. Frontiers in Immunology
- 42. Frontiers in Oncology
- 43. Frontiers in Public Health
- 44. Gene & Protein in Disease
- 45. Genes and Diseases
- 46. Heliyon
- 47. Human Vaccines & Immunotherapeutics
- 48. ImmunoTargets and Therapy
- 49. International Immunopharmacology
- 50. International Journal of Environmental Research and Public Health
- 51. International Journal of Molecular Sciences

- 52. International Journal of Nanomedicine
- 53. iScience
- 54. Journal of Cancer
- 55. Journal of Cancer Survivorship
- 56. Journal of Clinical Medicine
- 57. Journal of Hematology & Oncology
- 58. Journal of Hepatocellular Carcinoma
- 59. Journal of Personalized Medicine
- 60. Journal of Pharmaceutical Analysis
- 61. Libyan Journal of Medicine
- 62. Med
- 63. Medical Sciences
- 64. Medicine
- 65. Neoplasma
- 66. Neuropsychiatric Disease and Treatment
- 67. Nutrients
- 68. Oncology Research
- 69. OncoTargets and Therapy
- 70. Open Access Surgery
- 71. Patient Preference and Adherence
- 72. PeerJ
- 73. Pharmaceuticals
- 74. Pharmacogenomics
- 75. PlosOne
- 76. Psychology, Health & Medicine
- 77. Psychology Research and Behavior Management
- 78. Research and Reports in Urology
- 79. Seminars in Cancer Biology
- 80. Tumor Discovery
- 81. World Journal of Surgical Oncology

- Stage di 4 mesi presso IRST Meldola nel 2014 su attività in degenza

APPARTENENZA A GRUPPI/ASSOCIAZIONI

Iscritto, dal 24 Settembre 2007, all'Albo dell'Ordine Provinciale dei Medici Chirurghi e degli Odontoiatri di Messina.

Membro ESMO (European Society for Medical Oncology) dal 2010

COMPETENZA DIGITALE

Ottima conoscenza del pacchetto Office (Word, Power Point, Excel) e di Internet

Ottima conoscenza delle procedure relative alla compilazione di cartella clinica in formato elettronico

Ottima conoscenza delle procedure relative all'utilizzo della piattaforma AIFA

ALTRE COMPETENZE

Hobbies:

-Linguistica comparata

-Lettura (saggistica)

-Etruscologia

-Culture preclassiche del Mediterraneo

-Geografia politica generale e per microaree
-Astronomia
-Numismatica

PATENTE DI GUIDA B

ULTERIORI INFORMAZIONI

INVITED SPEAKER (FACULTY) / ORAL PRESENTATIONS:

- **Presentazione dello studio IRST186.02: "Olaparib as salvage treatment for cisplatin-resistant Germ Cell Tumor"**. Intervento tenuto nel corso dell'"Oncology Science Conference - Il futuro inizia oggi" svoltasi a Milano il 23/11/2016.
- **"Circulating cell-free AR copy number variation and outcome to abiraterone in castration-resistant prostate cancer"**. Intervento tenuto nel corso del Convegno **"Ca.P. Days. Expert Symposium sul carcinoma prostatico"** tenutosi a Baveno (VB) nei giorni 07-08/04/2017. Intervento risultato vincitore del Concorso **"Esperienze di Real Life"** a margine del medesimo convegno
- **"Tumore vescicale: Linee guida e scelte terapeutiche nella malattia avanzata"**. Intervento tenuto nel corso del Convegno: **"Tumore muscolo-invasivo della vescica: un approccio multidisciplinare"** tenutosi a Rimini il 22/09/2017
- **"Gli schemi di mobilitazione in Oncologia"**. Intervento in qualità di relatore nell'ambito del progetto webinar dal titolo **"Move On Air: Principali protocolli di mobilitazione in onco-ematologia"**. Evento tenutosi in data 21 Novembre 2018
- Intervento in qualità di **Relatore/Docente** (Titolo dell'intervento: **"L'ottimale algoritmo terapeutico nel mRCC: lo stato dell'arte"**) nell'ambito dell'evento intitolato: **"Help Desk in mRCC. Share the clinical experience"** tenutosi a Meldola (FC) in data 10 Luglio 2019
- Intervento in qualità di **Relatore/Docente** nell'ambito del Corso FaD **"4-RCC TALKS LIVE - Un possibile trattamento su misura del Paziente"**, svoltosi online il 9 novembre 2021.
- Intervento in qualità di **Relatore/Docente** (Titolo dell'intervento: **"L'informativa, il Consenso Informato e la Privacy del paziente"**) nell'ambito dell'evento intitolato **"CLINICAL TRIAL ACADEMY: CORSO DI ALTA FORMAZIONE IN RICERCA CLINICA - 1st EDITION"**, tenutosi a Bertinoro (FC) in data 22 Novembre 2022
- Intervento in qualità di **Relatore/Docente** (Titolo dell'intervento: **"Sviluppi dell'immunoterapia nei tumori uroginecologici"**) nell'ambito dell'evento intitolato: **"Percorsi Multidisciplinari per la Gestione degli eventi avversi: Focus su immunoterapia e Antibody-Drug Conjugates nei Tumori Mammari e Uroginecologici"**, tenutosi a Meldola (FC) in data 12 Dicembre 2023
- Intervento in qualità di **Relatore/Docente** (Titolo dell'intervento **"Neoplasie Urologiche"**) nell'ambito del corso **"ONCO-TIPS - Istruzioni d'uso per futuri oncologi"**, ciclo di incontri volti all'aggiornamento dei medici in formazione specialistica, tenutosi a Meldola (FC) in data 03 Aprile 2024
- Intervento in qualità di **Relatore/Docente** (Titolo dell'intervento: **"Luci e Ombre del Consenso Informato: tra Etica, Privacy e Autonomia nella scelta"**) nell'ambito dell'evento intitolato **"CLINICAL TRIAL ACADEMY: CORSO DI ALTA FORMAZIONE IN RICERCA CLINICA - 3rd EDITION"**, tenutosi a Bertinoro (FC) in data 24 Maggio 2024
- Intervento in qualità di **Relatore/Docente** (Titolo dell'intervento: **"Consenso informato: accompagnare il paziente verso una scelta consapevole"**) nell'ambito dell'evento intitolato **"Etica e Responsabilità nella Sperimentazione Clinica"** tenutosi a Meldola (FC) in data 09 Dicembre 2024
- Intervento in qualità di **Relatore** (Titolo dell'intervento: **"Le prossime frontiere nel trattamento del tumore uroteliale"**) nell'ambito dell'evento intitolato **"Ricerca Straordinaria in Oncologia ed Ematologia - come la ricerca clinica ha cambiato e cambierà la pratica clinica"** tenutosi a Meldola (FC) in data 18 Maggio 2026

PUBBLICAZIONI IN EXTENSO

- Urbini M, Eleveld TF, Polano M, Scarpi E, Menna C, Gianni C, Janssen FW, Schepisi G, Gurioli G, Kucerova L, Gillis AJM, Virga A, Bleve S, Rosti G, Ulivi P, Mego M, Looijenga LHJ, De Giorgi U. Impact of Circulating Tumor DNA and Copy-Number Alterations on Clinical Outcome in Relapsed/Refractory Germ Cell Tumors Treated With Salvage High-Dose Chemotherapy. **J Clin Oncol.** 2026 Feb 19;JCO2502159. doi: 10.1200/JCO-25-02159. Online ahead of print.

- **Schepisi G**, Conteduca V, Lolli C, Medri M, De Giorgi U. Taxane-related nail toxicity. *Lancet Oncology* Vol. 16, No. 7, e310–e311, July 2015
- **Schepisi G**, Banna GL, De Giorgi U. Consider Quality of Life to Improve Quality of Cancer Guidelines. *JAMA Intern Med.* 2017 Oct 1;177(10):1537. doi: 10.1001/jamainternmed.2017.3694
- **Schepisi G**, Santoni M, Massari F, Gurioli G, Salvi S, Conteduca V, Montironi R, De Giorgi U. Urothelial cancer: inflammatory mediators and implications for immunotherapy. *BioDrugs.* 2016 May 13.
- **Schepisi G**, De Padova S, Scarpi E, Lolli C, Gurioli G, Menna C, Burgio SL, Rossi L, Gallà V, Casadio V, Salvi S, Conteduca V, De Giorgi U. Vitamin D status among long-term survivors of testicular cancer. *Oncotarget.* 2016 Dec 24. doi: 10.18632/oncotarget.14167
- **Schepisi G**, Farolfi A, Conteduca V, Martignano F, De Lisi D, Ravaglia G, Rossi L, Menna C, Bellia SR, Barone D, Gunelli R, De Giorgi U. Immunotherapy for Prostate Cancer: Where We Are Headed. *Int J Mol Sci.* 2017 Dec 5;18(12). pii: E2627. doi: 10.3390/ijms18122627.
- **Schepisi G**, De Padova S, De Lisi D, Casadei C, Meggiolaro E, Ruffilli F, Rosti G, Lolli C, Ravaglia G, Conteduca V, Farolfi A, Grassi G, De Giorgi U. Psychosocial issues in long-term survivors of testicular cancer. *Front Endocrinol (Lausanne).* 2019 Feb 25;10:113. doi: 10.3389/fendo.2019.00113. eCollection 2019.
- **Schepisi G**, Brighi N, Cursano MC, Gurioli G, Ravaglia G, Altavilla A, Burgio SL, Testoni S, Menna C, Farolfi A, Casadei C, Tonini G, Santini D, De Giorgi U. Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors. *J Oncol.* 2019 Sep 19;2019:7317964. doi: 10.1155/2019/7317964. eCollection 2019.
- **Schepisi G**, Cursano MC, Casadei C, Menna C, Altavilla A, Lolli C, Cerchione C, Paganelli G, Santini D, Tonini G, Martinelli G, De Giorgi U. CAR-T cell therapy: a potential new strategy against prostate cancer. *J Immunother Cancer.* 2019 Oct 16;7(1):258. doi: 10.1186/s40425-019-0741-7
- **Schepisi G**, Conteduca V, Casadei C, Gurioli G, Rossi L, Gallà V, Cursano MC, Brighi N, Lolli C, Menna C, Farolfi A, Burgio SL, Altavilla A, Martinelli G, De Giorgi U. Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors. *Front Oncol.* 2020 Sep 23;10:565857. doi: 10.3389/fonc.2020.565857. eCollection 2020.
- **Schepisi G**, Casadei C, Toma I, Poti G, Iaia ML, Farolfi A, Conteduca V, Lolli C, Ravaglia G, Brighi N, Altavilla A, Martinelli G, De Giorgi U. Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy. *Cancers (Basel).* 2021 Feb 17;13(4):840. doi: 10.3390/cancers13040840.
- **Schepisi G**, Gianni C, Bleve S, De Padova S, Menna C, Lolli C, Filograna A, Conteduca V, Urbini M, Gallà V, Casadei C, Rosti G, De Giorgi U. Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review. *Int J Mol Sci.* 2021 May 13;22(10):5145. doi: 10.3390/ijms22105145.
- **Schepisi G**, Gianni C, Cursano MC, Gallà V, Menna C, Casadei C, Bleve S, Lolli C, Martinelli G, Rosti G and De Giorgi U (2023) Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors. *Front. Immunol.* 14:1118610. doi: 10.3389/fimmu.2023.1118610
- **Schepisi G**, Gianni C, Palleschi M, Bleve S, Casadei C, Lolli C, Ridolfi L, Martinelli G, De Giorgi U. The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer. *Cancers (Basel).* 2023 Mar 4;15(5):1597. doi: 10.3390/cancers15051597.
- **Schepisi G**, Urbini M, Casadei C, Gallà V, Rossetti S, Basso U, Lolli C, Gurioli G, Petracci E, Cecere SC, Ventriglia J, Zampiga V, Miserocchi A, Cangini I, De Santis I, Di Napoli M, Menna C, Mambelli G, Pignata S, De Giorgi U. Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trial. *ESMO Open.* 2025 May;10(5):105056. doi: 10.1016/j.esmoop.2025.105056. Epub 2025 Apr 24.

- Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; **ARAMIS Investigators (... Schepisi G ...)** Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. *N Engl J Med.* 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671
- Farolfi A, **Schepisi G**, Conteduca V, Burgio SL, Lolli C, De Giorgi U. Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma. *Expert Opin Drug Metab Toxicol.* 2016 Sep; 12(9):1089-96. doi: 10.1080/17425255.2016.1214713
- Casadei C, **Schepisi G**, Menna C, Chovanec M, Gurioli G, Gallà V, Altavilla A, Marcellini M, Bellia SR, Lolli C, Mego M, Rosti G, De Giorgi U. Reclassification of good-risk seminoma: prognostic factors, novel biomarkers and implications for clinical management. *Future Oncol.* 2019 Mar 18. doi: 10.2217/fon-2018-0850
- Urbini M, **Schepisi G**, Bleve S, Virga A, Gianni C, Gurioli G, Ulivi P, De Giorgi U. Primary Mediastinal and Testicular Germ Cell Tumors in Adolescents and Adults: A Comparison of Genomic Alterations and Clinical Implications. *Cancers (Basel)* 2021 Oct; 13(20): 5223. Published online 2021 Oct 18. doi: 10.3390/cancers13205223
- Brighi N, **Schepisi G**, Conteduca V, Scarpi E, Caroli P, Matteucci F, Lolli C. Validation of a Combined Prognostic Score Using Plasma Tumor DNA and Clinical Features in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Taxanes. *Onco Targets Ther.* 2025 May 23;18:667-677. doi: 10.2147/OTT.S509285. ECollection 2025.
- Giunta EF, **Schepisi G**, Bleve S, Serra R, Brighi N, Torresan I, Tassinari E, Zanuccoli S, Lolli C. Neuroendocrine prostate cancer (NEPC) in focus: state of the art and future perspectives. *Discov Oncol.* 2026 Feb 14. doi: 10.1007/s12672-026-04482-7. Online ahead of print.
- Martignano F, Rossi L, Maugeri A, Gallà V, Conteduca V, De Giorgi U, Casadio V, **Schepisi G**. Urinary RNA-based biomarkers for prostate cancer detection. *Clin Chim Acta.* 2017 Oct; 473:96-105. doi: 10.1016/j.cca.2017.08.009. Epub 2017 Aug 12
- Rossi L, Martignano L, Gallà V, Maugeri A, **Schepisi G**. Impact of non-pulmonary visceral metastases in the prognosis and practice of metastatic testicular germ cell tumors. *Oncology Reviews.* 2016;10(1). DOI: 10.4081/oncol.2016.292
- Gianni C, Palleschi M, **Schepisi G**, Casadei C, Bleve S, Merloni F, Sirico M, Sarti S, Cecconetto L, Di Menna G, Schettini F, De Giorgi U. Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment. *Front Oncol.* 2022 Aug 8;12:882896. doi: 10.3389/fonc.2022.882896.
- De Padova S, Urbini M, **Schepisi G**, Virga A, Meggiolaro E, Rossi L, Fabbri F, Bertelli T, Ulivi P, Ruffilli F, Casadei C, Gurioli G, Rosti G, Grassi L, De Giorgi U. Immunosenescence in Testicular Cancer Survivors: Potential Implications of Cancer Therapies and Psychological Distress. *Front Oncol.* 2021 Jan 15;10:564346. doi: 10.3389/fonc.2020.564346. eCollection 2020.
- Casadei C, Dizman N, **Schepisi G**, Cursano MC, Basso U, Santini D, Pal SK, De Giorgi U. Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. *Ther Adv Med Oncol.* 2019 Nov 25;11:1758835919890285. doi: 10.1177/1758835919890285. eCollection 2019.
- Lolli C, Gallà V, **Schepisi G**, Barone D, Burgio SL, Maugeri A, Vertogen B, Amadori D, De Giorgi U. A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer. *Oncologist.* 2017 Jul;22(7):784-e74. doi: 10.1634/theoncologist.2017-0154
- Salvi S, Casadio V, Conteduca V, Lolli C, Gurioli G, Martignano F, **Schepisi G**, Testoni S, Scarpi E, Amadori D, Calistri D, Attard G, De Giorgi U. Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. *Oncotarget.* 2016 May 13. doi: 10.18632/oncotarget.9341.
- De Lisi D, De Giorgi U, Lolli C, **Schepisi G**, Conteduca V, Menna C, Tonini G, Santini D, Farolfi A. Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? *Expert Opin Drug Metab Toxicol.* 2018 Apr;14(4):461-467. doi: 10.1080/17425255.2018.1455826
- Lolli C, Medri M, Ricci M, **Schepisi G**, Filograna A, De Giorgi U, Stanganelli I. Vitiligo-like lesions in a patient treated with nivolumab for renal cell carcinoma. *Medicine (Baltimore).* 2018 Dec;97(52):e13810
- Gurioli G, Conteduca V, Lolli C, **Schepisi G**, Gargiulo S, Altavilla A, Casadei C, Scarpi E, De Giorgi U.

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide. *Front Oncol.* 2020 Sep 24;10:567809. doi: 10.3389/fonc.2020.567809. eCollection 2020.

- Romano FJ, Rossetti S, Conteduca V, **Schepisi G**, Cavaliere C, Di Franco R, Lamantia E, Castaldo L, Nocerino F, Ametrano G, Cappuccio F, Malzone G, Montanari M, Vanacore D, Quagliariello V, Piscitelli R, Pepe MF, Berretta M, D'Aniello C, Perdonà S, Muto P, Botti G, Ciliberto G, Veneziani BM, De Falco F, Maiolino P, Caraglia M, Montella M, De Giorgi U, Facchini G. Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review. *Oncotarget.* 2016 Nov 3. doi: 10.18632/oncotarget.13063

- Conteduca V, Caffo O, Lolli C, Aieta M, Scarpi E, Bianchi E, Maines F, **Schepisi G**, Salvi S, Massari F, Carrozza F, Vecchia A, Chiuri VE, Campadelli E, Facchini G, De Giorgi U. Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone. *Prostate.* 2017 Jun;77(9):1012-1019. doi: 10.1002/pros.23357

- Conteduca V, Scarpi E, Caroli P, Salvi S, Lolli C, Burgio SL, Menna C, **Schepisi G**, Testoni S, Gurioli G, Paganelli G, Casadio V, Matteucci F, De Giorgi U. Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer. *Sci Rep.* 2017 Nov 14;7(1):15541. doi: 10.1038/s41598-017-15928-y

- Conteduca V, Caffo O, Galli L, Maugeri A, Scarpi E, Maines F, Chiuri VE, Lolli C, Kinspergher S, **Schepisi G**, Santoni M, Santini D, Fratino L, Burgio SL, Salvi S, Menna C, De Giorgi U. Association among metabolic syndrome, inflammation, and survival in prostate cancer. *Urol Oncol.* 2018 May;36(5):240.e1-240.e11. doi: 10.1016/j.urolonc.2018.01.007. Epub 2018 Mar 2

- Salvi S, Conteduca V, Lolli C, Testoni S, Casadio V, Zaccheroni A, Rossi L, Burgio SL, Menna C, **Schepisi G**, De Giorgi U. AR Copy Number and AR Signaling-directed Therapies in Castration resistant Prostate Cancer. *Curr Cancer Drug Targets.* 2018;18(9):869-876. doi: 10.2174/1568009617666171122145852.

-Conteduca V, Scarpi E, Salvi S, Casadio V, Lolli C, Gurioli G, **Schepisi G**, Wetterskog D, Farolfi A, Menna C, De Lisi D, Burgio SL, Beltran H, Attard G, De Giorgi U. Plasma androgen receptor and serum chromogranin A in advanced prostate cancer. *Sci Rep.* 2018 Oct 18;8(1):15442.

-Conteduca V, Gurioli G, Rossi L, Scarpi E, Lolli C, **Schepisi G**, Farolfi A, De Lisi D, Gallà V, Burgio SL, Menna C, Amadori A, Losi L, Amadori D, Costi MP, De Giorgi U. Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer. *BMC Cancer.* 2018 Dec 19;18(1):1267

- Conteduca V, Jayaram A, Romero-Laorden N, Wetterskog D, Salvi S, Gurioli G, Scarpi E, Castro E, Marin-Aguilera M, Lolli C, **Schepisi G**, Maugeri A, Wingate A, Farolfi A, Casadio V, Medina, Puente J, Vidal MJ, Morales-Barrera RI, Villa-Guzmán JC, Hernando S, Rodriguez-Vida A, González del-Alba A, Mellado B, Gonzalez-Billalabeitia E, Olmos D, Attard G, De Giorgi U. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. *Eur Urol* 2019;75(3):368-373

- De Padova S, Casadei C, Berardi A, Bertelli T, Filograna A, Cursano MC, Menna C, Burgio SL, Altavilla A, **Schepisi G**, Prati S, Montalti S, Chovanec M, Banna GL, Grassi L, Mego M, De Giorgi U. Caregiver Emotional Burden in Testicular Cancer Patients: From Patient to Caregiver Support. *Front Endocrinol (Lausanne).* 2019 May 28;10:318. doi: 10.3389/fendo.2019.00318. eCollection 2019. Review

- Conteduca V, Castro E, Wetterskog D, Scarpi E, Jayaram A, Romero-Laorden N, Olmos D, Gurioli G, Lolli C, Sáez MI, Puente J, **Schepisi G**, Salvi S, Wingate A, Medina A, Querol-Niñerola R, Marin-Aguilera M, Arranz JA, Fornarini G, Basso U, Mellado B, Gonzalez-Billalabeitia E, Attard G, De Giorgi U. Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. *Eur J Cancer.* 2019 Jun 11;116:158-168. doi: 10.1016/j.ejca.2019.05.007

- Conteduca V, Scarpi E, Matteucci F, Caroli P, Ravaglia G, Fantini L, Gurioli G, **Schepisi G**, Wetterskog D, Menna C, Burgio SL, Lolli C, Paganelli G, Attard G, De Giorgi U. A multimodal approach to outcome prediction in metastatic castration-resistant prostate cancer by integrating functional imaging and plasma DNA analysis. DOI: 10.1200/PO.18.00302 JCO Precision Oncology - published online April 25, 2019

- Lolli C, De Lisi D, Conteduca V, Gurioli G, Scarpi E, **Schepisi G**, Ravaglia G, Menna C, Farolfi A,

Altavilla A, Burgio SL, Tonini G, Santini D, De Giorgi U. Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide. *Prostate*. 2019 Aug;79(11):1211-1220. doi: 10.1002/pros.23804

-Conteduca V, Gurioli G, Brighi N, Lolli C, **Schepisi G**, Casadei C, Burgio SL, Gargiulo S, Ravaglia G, Rossi L, Altavilla A, Farolfi A, Menna C, Colangione SP, Pulvirenti M, Romeo A, De Giorgi U. Plasma Androgen Receptor in Prostate Cancer. *Cancers (Basel)*. 2019 Nov 4;11(11):1719. doi: 10.3390/cancers11111719.

- Brighi N, Farolfi A, Conteduca V, Gurioli G, Gargiulo S, Gallà V, **Schepisi G**, Lolli C, Casadei C, De Giorgi U. The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment. *Cancers (Basel)*. 2019 Dec 4;11(12):1935. doi: 10.3390/cancers11121935.

- Banna GL, Urzia V, Benanti C, Pitre A, Lipari H, Di Quattro R, De Giorgi U, **Schepisi G**, Basso U, Bimbatti D, Rundo F, Libra M, Malatino L. Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer. *Support Care Cancer*. 2020 Jan 20. doi: 10.1007/s00520-020-05311-5. Online ahead of print.

- Conteduca V, Caffo O, Scarpi E, Sepe P, Galli L, Fratino L, Maines F, Chiuri VE, Santoni M, Zanardi E, Massari F, Toma I, Lolli C, **Schepisi G**, Sbrana A, Kinspergher S, Cursano MC, Casadei C, Modonesi C, Santini D, Procopio G, De Giorgi U. Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy. *J Clin Med*. 2020 Jun 22;9(6):1950. doi: 10.3390/jcm9061950.

- Lolli C, Altavilla A, Conteduca V, Farolfi A, Casadei C, **Schepisi G**, Banna GL, De Giorgi U. A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma. *Crit Rev Oncol Hematol*. 2020 Sep; 153:103036. doi: 10.1016/j.critrevonc.2020.103036. Epub 2020 Jun 26.

- Conteduca V, Wetterskog D, Scarpi E, Romanel A, Gurioli G, Jayaram A, Lolli C, Tandefelt DG, **Schepisi G**, Casadei C, Wingate A, Matteucci F, Paganelli G, Gonzalez-Billalabeitia E, Demichelis F, De Giorgi U, Attard G. Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer. *Br J Cancer*. 2020 Sep; 123(6):982-987. doi: 10.1038/s41416-020-0969-5. Epub 2020 Jul 16.

- Altavilla A, Casadei C, Lolli C, Menna C, Ravaglia G, Gurioli G, Farolfi A, Brighi N, Conteduca V, Burgio SL, **Schepisi G**, Rossi L, Gargiulo S, Lisotti I, De Giorgi U. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer. *Expert Opin Pharmacother*. 2020 Dec; 21(17):2091-2099. doi: 10.1080/14656566.2020.1803281. Epub 2020 Aug 12.

- Cursano MC, Kopf B, Scarpi E, Menna C, Casadei C, **Schepisi G**, Lolli C, Altavilla A, Gallà V, Santini D, Tonini G, Chovanec M, Mego M, De Giorgi U. Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy. *Front Oncol*. 2020 Aug 14;10:1325. doi: 10.3389/fonc.2020.01325. eCollection 2020.

- Brighi N, Conteduca V, Lolli C, Gurioli G, **Schepisi G**, Palleschi M, Mariotti M, Casadei C, De Giorgi U. The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives. *Crit Rev Oncol Hematol*. 2021 Jan;157:103199. doi: 10.1016/j.critrevonc.2020.103199. Epub 2020 Dec 13.

- Del Re M, Conteduca V, Crucitta S, Gurioli G, Casadei C, Restante G, **Schepisi G**, Lolli C, Cucchiara F, Danesi R, De Giorgi U. Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide. *Prostate Cancer Prostatic Dis*. 2021 Jan 26. doi: 10.1038/s41391-020-00309-w. Online ahead of print.

- Conteduca V, Poti G, Caroli P, Russi S, Brighi N, Lolli C, **Schepisi G**, Romeo A, Matteucci F, Paganelli G, Marchetti P, De Giorgi U. Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging. *Ther Adv Med Oncol*. 2021 Feb 24;13:1758835920987654. doi: 10.1177/1758835920987654. eCollection 2021.

- Conteduca V, Brighi N, Conteduca D, Bleve S, Gianni C, **Schepisi G**, Iaia ML, Gurioli G, Lolli C, De Giorgi U. An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA. *Expert Rev Mol Diagn*. 2021 Jul;21(7):631-640. doi: 10.1080/14737159.2021.1935881. Epub

2021 Jun 14.

- Conteduca V, Wetterskog D, Castro E, Scarpi E, Romero-Laorden N, Gurioli G, Jayaram A, Lolli C, **Schepisi G**, Wingate A, Casadei C, Lozano R, Brighi N, Aragón IM, Marin-Aguilera M, Gonzalez-Billalabeitia E, Mellado B, Olmos D, Attard G, De Giorgi U. Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study. *Eur J Cancer*. 2021 Jul;152:49-59. doi: 10.1016/j.ejca.2021.04.025. Epub 2021 May 30.

- Brighi N, Conteduca V, Lolli C, Gurioli G, **Schepisi G**, Palleschi M, Mariotti M, Casadei C, De Giorgi U. Corrigendum to "The cyclin-dependent kinases pathway as a target for prostate cancer treatment: Rationale and future perspectives" [*Crit. Rev. Oncol. Hematol.* 157 (January) (2021) 103199]. *Crit Rev Oncol Hematol*. 2021 Aug;164:103401. doi: 10.1016/j.critrevonc.2021.103401. Epub 2021 Jul 16.

- Caffo O, Ortega C, Nolè F, Gasparro D, Mucciarini C, Aieta M, Zagonel V, Iacovelli R, De Giorgi U, Facchini G, Veccia A, Palesandro E, Verri E, Buti S, Razzini G, Bozza G, Maruzzo M, Ciccarese C, **Schepisi G**, Rossetti S, Maines F, Kinspergher S, Fratino L, Ermacora P, Nicodemo M, Giordano M, Sartori D, Scapoli D, Sabbatini R, Lo Re G, Morelli F, D'Angelo A, Vittimberga I, Lippe P, Carrozza F, Messina C, Galli L, Valcamonica F, Porta C, Pappagallo G, Aglietta M. Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. *Eur J Cancer*. 2021 Sep;155:56-63. doi: 10.1016/j.ejca.2021.06.016. Epub 2021 Aug 3.

- Conteduca V, Scarpi E, Farolfi A, Brighi N, Rossi L, Gurioli G, Lolli C, **Schepisi G**, Bleve S, Gianni C, Virga A, Altavilla A, Burgio SL, Menna C, De Giorgi U. Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma. *Front Oncol*. 2021 Jul 21;11:716467. doi: 10.3389/fonc.2021.716467. eCollection 2021.

- Conteduca V, Scarpi E, Wetterskog D, Brighi N, Ferroni F, Rossi A, Romanel A, Gurioli G, Bleve S, Gianni C, **Schepisi G**, Lolli C, Cortesi P, Matteucci F, Barone D, Paganelli G, Demichelis F, Beltran H, Attard G, De Giorgi U. Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients. *Int J Cancer*. 2022 Apr 1;150(7):1166-1173. doi: 10.1002/ijc.33834. Epub 2021 Oct 13.

- Conteduca V, Scarpi E, Caroli P, Lolli C, Gurioli G, Brighi N, Poti G, Farolfi A, Altavilla A, **Schepisi G**, Matteucci F, Paganelli G, De Giorgi U. Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome. *Mol Oncol*. 2022 Jan;16(2):538-548. doi: 10.1002/1878-0261.13120. Epub 2021 Nov 9.

- Gurioli G, Conteduca V, Brighi N, Scarpi E, Basso U, Fornarini G, Mosca A, Nicodemo M, Banna GL, Lolli C, **Schepisi G**, Ravaglia G, Bondi I, Ulivi P, De Giorgi U. Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel. *BMC Med*. 2022 Jan 31;20(1):48. doi: 10.1186/s12916-022-02244-0

- Conteduca V, Casadei C, Scarpi E, Brighi N, **Schepisi G**, Lolli C, Gurioli G, Toma I, Poti G, Farolfi A, De Giorgi U. Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. *Cancers (Basel)*. 2022 Apr 29;14(9):2219. doi: 10.3390/cancers14092219

- Bleve S, Cursano MC, Casadei C, **Schepisi G**, Menna C, Urbini M, Gianni C, De Padova S, Filograna A, Gallà V, Rosti G, Barone D, Chovanec M, Mego M, De Giorgi U. Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular Cancer. *Front Oncol*. 2022 Jun 10;12:910087. doi: 10.3389/fonc.2022.910087. ECollection 2022

- Gianni C, Palleschi M, **Schepisi G**, Casadei C, Bleve S, Merloni F, Sirico M, Sarti S, Cecconetto L, Di Menna G, Schettini F, De Giorgi U. Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment. *Front Oncol*. 2022 Aug 8;12:882896. doi: 10.3389/fonc.2022.882896. ECollection 2022.

- Conteduca V, Brighi N, **Schepisi G**, De Giorgi U. Immunogenomic profiles associated with response to life-prolonging agents in prostate cancer. *Br J Cancer*. 2023 Oct;129(7):1050-1060. doi: 10.1038/s41416-023-02354-3. Epub 2023 Jul 13.

- Farolfi A, Petracci E, Gurioli G, Tedaldi G, Casanova C, Arcangeli V, Amadori A, Rosati M, Stefanetti M, Burgio SL, Cursano MC, Lolli C, Zampiga V, Cangini I, **Schepisi G**, De Giorgi U. Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients. *Front Oncol*. 2023 Aug 16;13:1221096. doi: 10.3389/fonc.2023.1221096. ECollection 2023.

-Brighi N, Conteduca V, Gurioli G, Scarpi E, Cursano MC, Bleve S, Lolli C, **Schepisi G**, Casadei C, Gianni C, Ulivi P, De Giorgi U. Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial. *ESMO Open*. 2023 Dec;8(6):102036. doi: 10.1016/j.esmoop.2023.102036. Epub 2023 Oct 20.

- Urbini M, Bleve S, **Schepisi G**, Menna C, Gurioli G, Gianni C, De Giorgi U. Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors. *Int J Mol Sci*. 2023 Nov 28;24(23):16872. doi: 10.3390/ijms242316872.

- Conteduca V, Di Tullio P, Allamprese R, Bruno G, Lolli C, **Schepisi G**, Rosano A, Giordano G, Garofoli M, Chiuri VE, Fratino L, Zanardi E, Galli L, Massari F, Falagario U, Rescigno P, Fornarini G, Sanguedolce F, Santini D, Procopio G, Caffo O, Carrieri G, Landriscina M, De Giorgi U. Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care. *Prostate Cancer Prostatic Dis*. 2024 Feb 12. doi: 10.1038/s41391-024-00800-8. Online ahead of print.

- Casadei C, Scarpi E, Conteduca V, Gurioli G, Cursano MC, Brighi N, Lolli C, **Schepisi G**, Basso U, Fornarini G, Bleve S, Farolfi A, Altavilla A, Burgio SL, Giunta EF, Gianni C, Filograna A, Ulivi P, Olmos D, Castro E, De Giorgi U. Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study. *Eur Urol Open Sci*. 2024 Feb 7;61:44-51. doi: 10.1016/j.euros.2024.01.015. eCollection 2024 Mar.

- Maiorano BA, Di Maio M, Cerbone L, Maiello E, Procopio G, Roviello G, **MeetURO Group (...Schepisi G...)**. Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. *JAMA Netw Open*. 2024 Mar 4;7(3):e241215. doi: 10.1001/jamanetworkopen.2024.1215

- Giunta EF, Caroli P, Scarpi E, Altavilla A, Rossetti V, Marini I, Celli M, Casadei C, Lolli C, **Schepisi G**, Bleve S, Brighi N, Cursano MC, Paganelli G, Matteucci F, De Giorgi U. Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients. *Eur J Nucl Med Mol Imaging*. 2024 Aug 29. doi: 10.1007/s00259-024-06887-4.

- Serra R, Giunta EF, **Schepisi G**, Brighi N, Montanari D, Lolli C, Bleve S, Piras M, Palmieri G, Scartozzi M, Paliogiannis P, De Giorgi U. An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer. *Expert Rev Anticancer Ther*. 2024 Dec;24(12):1221-1227. doi: 10.1080/14737140.2024.2445152. Epub 2024 Dec 25.

- Conteduca V, Scarpi E, Rossi A, Ferroni F, Gurioli G, Bleve S, Gianni C, **Schepisi G**, Brighi N, Lolli C, Cursano MC, Virga A, Casadei C, Altavilla A, Farolfi A, Ulivi P, Barone D, Matteucci F, De Giorgi U. Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer. *Oncologist*. 2025 May 8;30(5):oyaf107. doi: 10.1093/oncolo/oyaf107.

- Bruno G, Natalicchio MI, Garofoli M, Lolli C, Rosano A, Tullio PD, Giordano G, Mancino A, Masucci M, Chiuri VE, Fratino L, Zanardi E, **Schepisi G**, Galli L, Massari F, Santoni M, Brighi N, Cornacchia E, Rescigno P, Fornarini G, Sanguedolce F, Santini D, Procopio G, Caffo O, Giorgi U, Landriscina M, Conteduca V. Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience. *Eur Urol Oncol*.

- Bleve S, Ravera F, Rodrigues S, Pederzoli F, Pakula H, Brighi N, Giunta EF, **Schepisi G**, Virga A, Gurioli G, Burgio SL, Fanelli GN, Butler LM, Nanus DM, Swinnen JV, Nuzzo PV, Lolli C, De Giorgi U, Loda M. Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor-targeting therapy. *Prostate Cancer Prostatic Dis.* 2026 Mar 13:10.1038/s41391-026-01100-z. doi: 10.1038/s41391-026-01100-z. Online ahead of print.

ABSTRACT

Aragona M, Samiani RA, Picone GS, Lupo G, Scorza N, Grasso C, **Schepisi G**, Altavilla G. Transpersonal therapy combined with best supportive care in hospice improve patient's quality of life and quality of death. XIV Congresso Nazionale AIOM – Roma 27-29 Ott 2012 (poster n° C29)

De Giorgi U, Maruzzo M, Santoni M, Massari F, Wheeler MJ, Scarpi E, Lolli C, Sotte V, Crabb SJ, Cascinu S, Basso U, **Schepisi G**. Systemic immune-inflammation index (SII) as prognostic/predictive factor in patients (pts) with metastatic renal cell cancer (mRCC) treated with sunitinib. *Journal of Clinical Oncology*, 2015 ASCO Annual Meeting (May 29 - June 2, 2015). Vol 33, No 15_suppl (May 20 Supplement), 2015: e15595

Conteduca V, Salvi S, Caroli P, Scarpi E, Lolli C, Burgio SL, Menna C, **Schepisi G**, Bianchi E, Gurioli G, Paganelli G, Casadio V, Matteucci F, Attard G, De Giorgi U. The correlation between circulating cell-free AR and CYP17A1 copy number variations and tumor burden estimated by 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. 40th ESMO - European Cancer Congress 2015 - Vienna, Austria - 25 Sep - 29 Sep 2015 (poster n° 2577)

Conteduca V, Casadio V, Caroli P, Scarpi E, Lolli C, Menna C, Bianchi E, **Schepisi G**, Testoni S, Gurioli G, Salvi S, Amadori D, Paganelli G, Matteucci F, Attard G, De Giorgi U. Increased choline uptake in androgen receptor (AR) copy number gain castration-resistant prostate cancers (CRPC). ESMO Congress 2016 – Copenhagen, Denmark – 07-11 Oct 2016 (poster n° 737P)

Conteduca V, Salvi S, Casadio V, Lolli C, Gurioli G, **Schepisi G**, Martignano F, Menna C, Burgio SL, Testoni S, Attard G, De Giorgi U. Circulating androgen receptor and serum chromogranin A in castration-resistant prostate cancers (CRPC) patients treated with abiraterone and enzalutamide. 2017 Genitourinary Cancers Symposium – Orlando, Florida – 16-18 Feb 2017. *J Clin Oncol* 35, 2017 (suppl 6S; abstract 160)

Salvi S, Conteduca V, Casadio V, Fici P, Gurioli G, Martignano F, Basso U, Fornarini G, Lolli C, **Schepisi G**, Testoni S, Calistri D, De Giorgi U. Circulating tumor cells as liquid biopsy for castration resistant prostate cancer patients treated with cabazitaxel. ESMO 2017 – Madrid, Spagna – 08 Sep-12 Sep 2017 (poster n°131P)

Conteduca V, Salvi S, Caroli P, Scarpi E, **Schepisi G**, Lolli C, Wetterskog D, Burgio SL, Menna C, Casadio V, Matteucci F, G, Paganelli G, Attard G, De Giorgi U. Combining functional imaging with circulating biomarker analysis to improve prognostication of metastatic castration-resistant prostate cancer (mCRPC) ESMO 2017 – Madrid, Spagna – 08 Sep-12 Sep 2017. *Annals of Oncology* (2017) 28 (suppl_5): v269-v294. 10.1093/annonc/mdx370 (Poster n° 820P)

Conteduca V, Jayaram A, Romero-Laorden N, Wetterskog D, Salvi S, Gurioli G, Scarpi E, Castro E, Marin M, Lolli C, **Schepisi G**, Wingate A, Medina A, Fornarini G, Basso U, Mellado B, Gonzalez-Billalabeitia E, Olmos D, Attard G, De Giorgi U. Plasma androgen receptor (pAR) status and activity of taxanes in metastatic castration resistant prostate cancer (mCRPC) ASCO 2018. *J Clin Oncol* 36, 2018 (suppl; abstr 5074)

Conteduca V, Wetterskog D, Scarpi E, Romanel A, Gurioli G, Anuradha J, Lolli C, **Schepisi G**, Casadei C, Menna C, Wingate A, Demichelis F, De Giorgi U, Attard G. Circulating tumour DNA fraction (ctDNA) as a surrogate predictive biomarker in metastatic castration-resistant prostate cancer (mCRPC). ASCO 2019 *J Clin Oncol* 37, 2019 (suppl; abstr 5039)

Conteduca V, Castro E, Wetterskog D, Scarpi E, Romero-Laorden N, Gurioli G, Jayaram A, Lolli G,

Schepisi G, Wingate A, Casadei C, Lozano R, Brighi N, Aragon I, Marín-Aguilera M, González-Billalabeitia E, Mellado B, Olmos D, Attard D, De Giorgi U. Use of plasma androgen receptor (AR) testing to optimize docetaxel chemotherapy in castration-resistant prostate cancer (CRPC): A multicenter biomarker study. ASCO 2020 Journal of Clinical Oncology 2020 38:15_suppl, 5546-5546

De Giorgi U, **Schepisi G**, Gurioli G, Pisano C, Basso U, Lolli C, Petracci E, Casadei C, Cecere SC, Attademo L, Clemente A, Zampiga V, Gallà V, Cangini I, Di Napoli M, Valmorri L, Pignata S. Olaparib as salvage treatment for advanced germ cell tumors after chemotherapy failure – results of the open label, single-arm, IGG-02 phase II trial. Poster ASCO 2020 abstr. 5058

Conteduca V, Scarpi E, Wetterskog D, Ferroni F, Rossi A, Romanel A, Gurioli G, Bleve S, Gianni C, Brighi N, **Schepisi G**, Lolli C, Cortesi P, Barone D, Demichelis F, Paganelli G, Beltran H, Attard G, De Giorgi U. Association of plasma tumor DNA (ptDNA) with increased risk of venous thromboembolism (VTE) in metastatic castration resistant prostate cancer patients (mCRPC). J Clin Oncol 39, 2021 (suppl 15; abstr 5048)

Conteduca V, Scarpi E, Rossi A, Ferroni F, Gurioli G, Bleve S, Gianni C, **Schepisi G**, Brighi N, Lolli C, Cursano MC, Virga A, Casadei C, Altavilla A, Farolfi A, Ulivi P, Barone D, Matteucci F, Paganelli G, De Giorgi U. Association of changing bone metastatic (mets) patterns with dynamics of circulating tumor DNA (ctDNA) in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 40, 2022 (suppl 6; abstr 152)

Altavilla A, Caroli P, Giunta EF, Scarpi E, Rossetti V, Casadei C, Lolli C, **Schepisi G**, Bleve S, Cursano MC, Gasperoni L, Matteucci F, De Giorgi U. Impact of 68Ga-PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide. J Clin Oncol 41, 2023 (suppl 6; abstr 48)

De Giorgi U, Casadei C, Conteduca V, Gurioli G, Scarpi E, Cursano MC, Brighi N, Lolli C, **Schepisi G**, Basso U, Fornarini G, Bleve S, Farolfi A, Altavilla A, Olmos D, Castro E. Inherited mutations in DNA damage gene repair (gDDR) in Italian men with metastatic prostate cancer. J Clin Oncol 41, 2023 (suppl 6; abstr 223)

Bleve S, Ravera F, Rodrigues S, Omar M, Giunta EF, Pederzoli F, Pakula H, Altavilla A, Brighi N, Gurioli G, Cursano MC, Casadei C, Lolli C, **Schepisi G**, Nanus DM, Nuzzo PV, De Giorgi U, Loda M. Lipidomic profiling as a biomarker for prostate cancer diagnosis and response to enzalutamide (Enza). ASCO 2024. J Clin Oncol 42, 2024 (suppl 4; abstr 217)

Appendice 1. Breve riassunto della formazione rilevante per UCF1

Evidenze UCF1

Ingresso in organigramma Fase I	15 Luglio 2016
Certificato Advanced Life Support (ALS)	23-24 Ottobre 2025
Certificato Basic Life support and Defibrillator (BLSD)	06 Maggio 2025
Certificato training Good Clinical Practice E6R3 (GCP)	16 Luglio 2025

Appendice 2.

PARTECIPAZIONE AI
SEGUENTI STUDI
CLINICI, CONDOTTI IN
QUALITÀ DI
PRINCIPAL
INVESTGATOR (PI)

1. A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors (**FASE 1 XL184-021**)
2. A multinational, randomised, double-blind, placebo-controlled, phase III efficacy and safety study of odm-201 in men with high-risk non-metastatic castration-resistant prostate cancer

SUB-INVESTIGATOR

(ARAMIS) (PI)

3. A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy. **(MK-5684-003) (PI)**
4. A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) **(MK-5684-004) (PI)**
5. A Phase 3, Randomized, Open-Label Study Of Pf-06821497 (Mevrometostat) In Combination With Enzalutamide Compared With Enzalutamide Or Docetaxel In Participants With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate **(MEVPRO-1) (PI)**
6. A Phase 3, Randomized, Double Blind, Placebo Controlled Study Of Pf-06821497 (Mevrometostat) With Enzalutamide In Metastatic Castration Resistant Prostate Cancer **(MEVPRO-2) (PI)**
7. A Phase 3, Randomized, open-label study of Nivolumab combined with Ipilimumab versus Sunitinib monotherapy in subjects with previously untreated, advanced or metastatic renal cell carcinoma (CheckMate 214, CHECKpoint pathway and nivolumab clinical Trial Evaluation 214) - **CA209214** (Bristol-Myers Squibb Company)
8. **GO27983**: A Phase Ib/II study of GDC-0068 or GDC-0980 with Abiraterone Acetate versus Abiraterone Acetate in patients with castration-resistant prostate cancer previously treated with Docetaxel-based chemotherapy - (Genentech, Inc)
9. Chemotherapy plus Enzalutamide in first line therapy for castration resistant prostate cancer. A multicentric randomized phase II study. **Ch.E.I.R.O.N.** Trial
10. A multicenter, single-arm, open-label, post-marketing safety study to evaluate the risk of seizure among subjects with metastatic Castration-Resistant Prostate Cancer (mCRPC) treated with Enzalutamide who are at potential increased risk of seizure (UPWARD)- **9785-CL-0403** (Astellas Pharma Global Development, Inc.)
11. A Phase 3, randomized, double-blind, placebo-controlled study of continued Enzalutamide treatment beyond progression in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer. MDV3100-10 (Medivation Inc.)
12. **PROSPER**: A multinational, phase 3, randomized, double-blind, placebo-controlled, efficacy and safety study of Enzalutamide in patients With Nonmetastatic Castration-Resistant Prostate Cancer. MDV3100-14 (Medivation, Inc.)
13. A phase I, open-label, multi-center, dose escalation study of oral BGJ398, a pan FGF-R kinase inhibitor, in adult patients with advanced solid malignancies - **CBGJ398X2101** (Novartis)
14. A multicenter, randomized, double-blind, placebo-controlled, phase III study of ARN-509 in men with non-metastatic (M0) castration-resistant prostate cancer - ARN-509-003 (Aragon Pharmaceuticals, Inc) (**SPARTAN** Study)
15. A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy **(METEOR)**
16. A double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of maintenance therapy with PankoMab-GEX™ after chemotherapy in patients with recurrent epithelial ovarian carcinoma - **GEXMab 25201** (Glycotope GmbH)
17. Olaparib as salvage treatment for cisplatin-resistant germ cell tumor. Protocol Code: **IRST186.02**
18. Olaparib **D081DC00008**: A randomized, double blind, placebo-controlled, multicentre phase II study to compare the efficacy, safety and tolerability of Olaparib versus placebo when given in addition to Abiraterone treatment in patients with metastatic castrate-resistant prostate cancer who have received prior chemotherapy containing Docetaxel (Quintiles)
19. A randomised, parallel-group, open-label Phase II trial of the immunological effects of three regimens of GX301 vaccination in castration-resistant prostate cancer patients who have achieved response to first-line chemotherapy. **MED-GX301-02** (Laboratoires Leurquin Mediolanum S.A.S.)
20. A Phase 3, randomized, controlled study of Cabozantinib (XL184) vs Everolimus in subjects with metastatic renal cell carcinoma that has progressed after prior VEGFR tyrosine kinase inhibitor therapy. **XL184-308** (Exelixis, Inc.)

21. A phase III, open-label, multicenter, randomized study to investigate the efficacy and safety of MPDL3280A (anti-PD-L1 antibody) compared with chemotherapy in patients with locally advanced or metastatic urothelial bladder cancer after failure with platinum-containing chemotherapy. **GO29294** (F. Hoffmann-La Roche Ltd)
22. A randomized, double-blind, comparative study of Abiraterone acetate plus low-dose prednisone plus Androgen Deprivation Therapy (ADT) versus ADT alone in newly diagnosed subjects with high-risk, metastatic Hormone-Naive Prostate Cancer (mHNPC) - JNJ-212082 (Janssen Research & Development, LLC)
23. A Randomized, Double-blind, Comparative Study of ZYTIGA® (Abiraterone Acetate) Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) (**LATITUDE**)
24. Phase III International, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last Platinum (**INOVATYON** Study)
25. A European PROspective Observational Study Assessing the Effectiveness and Outcomes Associated with Enzalutamide Treatment in Patients with Metastatic Castration Resistant ProState CancEr (mCRPC). 9785-MA-1002 (**PREMISE** Study)
26. **EMBARK**: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy. MDV3100-13
27. **ARMOR3-SV**: A Phase 3 Randomized, open-label, multicenter controlled Study of Galeterone compared to Enzalutamide in men expressing androgen receptor splice variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
28. **SOLO-3**: A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients carrying germline BRCA1/2 Mutations.
29. **WO29636**: A Phase III, Open-Label, Multicenter, Randomizes Study of Atezolizumab (Anti-PD-L1 Antibody) versus observation as adjuvant therapy in patients with PD-L1-selected, high-risk Muscle-Invasive Bladder Cancer after Cystectomy.
30. D419BC00001 (**DANUBE**): A Phase III, Randomized, Open-label, Controlled, Multi Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Stage IV Urothelial Bladder Cancer
31. **42756493BLC2001**: A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with FGFR Genomic Alterations
32. Study: Phase II study of oral PRednisone 5 mg bid plus EVERolimus in patients with metastatic renal cell cancer after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitors (**PREV** study)
33. Activity and safety of second line SOrafenib After Pazopanib in patients with metastatic renal cell carcinoma (**SOAP** Study)
34. A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy
35. A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide Who Are at Potential Increased Risk of Seizure
36. A phase I, open-label, multi-center, dose escalation study of oral BGJ398, a pan FGF-R kinase inhibitor, in adult patients with advanced solid malignancies
37. A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
38. A multinational, randomised, double-blind, placebo-controlled, phase III efficacy and safety study of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer.
39. A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naive Metastatic Castration-resistant Prostate

Cancer (mCRPC)

40. A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician's Choice Single Agent hemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients carrying germline BRCA12
41. A phase III, open-label, randomized study of atezolizumab (anti-PD-L1 antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma (**WO29637**)
42. Protocollo **AG41992** per l'accesso posttrial al WO29637
43. A prospective randomised phase III study of androgen deprivation therapy with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate cancer.
44. A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy
45. A phase III, randomized, open label, multicenter, controlled study of Galeterone compared to enzalutamide in men expressing androgen receptor splice variant-7 mRNA (AR-V7) metastatic castrate resistant prostate cancer (CRPC)
46. A phase III, open-label, multicenter, randomized study of atezolizumab (anti-PD-L1 antibody) versus observation as adjuvant therapy in patients with PD-L1-selected, high-risk muscle-invasive bladder cancer after cystectomy
47. A Phase III, Randomized, Open-label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Bladder Cancer
48. A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
49. A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma
50. A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (anti-PD-L1 antibody) in combination with gemcitabine/carboplatin versus gemcitabine/carboplatin alone in patients with untreated locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-based therapy
51. Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy (**KEYNOTE-199**)
52. Randomized phase III trial on Trabectedin (ET 743) vs clinician's choice chemotherapy in recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype patients
53. A phase 3, multicenter, multinational, randomized, open-label, parallel-arm study of avelumab* (MSB0010718C) plus best supportive care versus best supportive care alone in patients who completed first-line chemotherapy for unresectable locally advanced or metastatic urothelial cancer (**JAVELIN - B9991001**)
54. A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone.
55. A phase 3, multicenter, multinational, randomized, open-label, parallel-arm study of avelumab (msb0010718c) plus best supportive care versus best supportive care alone as a maintenance treatment in patients with locally advanced or metastatic urothelial cancer whose disease did not progress after completion of first-line platinum-containing chemotherapy
56. A phase 2, exploratory, multicenter, non randomized, single agent cohort study to determine best tumor response with trastuzumab emtansine in HER2 overexpressing solid tumors
57. An open label, single arm, multicenter safety study of atezolizumab in locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract
58. Axitinib In ADvanced / Metastatic Renal Cell Carcinoma - A Non-Interventional Study of Real World Treatment Outcomes in Patients Receiving 2nd Line Axitinib after 1st Line Sunitinib (**ADONIS**)
59. A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy in patients with renal cell carcinoma at high risk of developing metastasis following nephrectomy

60. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
61. A phase III, multicenter study of atezolizumab in combination with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer after failure of an androgen synthesis inhibitor and failure of, ineligibility for or refusal of a taxane regimen
62. A phase III, randomized, double-blind, placebo-controlled, multicentre trial testing ipatasertib plus abiraterone plus prednisone/prednisolone, relative to placebo plus abiraterone plus prednisone/prednisolone in adult male patients with asymptomatic or mildly symptomatic, previously untreated metastatic castration-resistant prostate cancer
63. A Phase III, open label, randomized study to assess the efficacy and safety of olaparib (Lynparza) versus enzalutamide or abiraterone acetate in men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have homologous recombination repair gene mutations
64. Multicenter, open-label phase 2 study of rucaparib in patients with metastatic castration-resistant prostate cancer associated with homologous recombination deficiency
65. A phase III, multicenter randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin and bevacizumab for patients with newly diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer
66. An open-label, multi-centre, safety study of fixed-dose durvalumab + tremelimumab combination therapy or durvalumab monotherapy in advanced solid malignancies.
67. A multinational phase 3, randomized, open-label, parallel group study to evaluate the safety and efficacy of relugolix in men with advanced prostate cancer
68. A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (**CLEAR**)
69. A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
70. Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer (**MITO END-3**)
71. Studio di Fase III, in aperto, randomizzato, controllato, multicentrico per valutare l'efficacia e la Sicurezza di Savolitinib vs Sunitinib, in pazienti con mutazione del gene MET nel Carcinoma a Cellule Renali di tipo Papillare, non resecabile e Localmente Avanzato o Metastatico
72. A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum- containing chemotherapy
73. A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (**THOR**)
74. A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (**TRITON2**)
75. A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (**TRITON3**)
76. A Phase 2 Open-label Extension Study for Subjects with Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study (**9785-CL-0123**)
77. A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide Who Are at Potential Increased Risk of Seizure (**9785-CL-0403**)
78. A Prospective OBServational STUdy Of Patients With Metastatic Castration Resistant Prostate Cancer Progressing After StanDard Hormonal Therapy Suitable For Abiraterone Acetate TrEatment (**ABITUDE**)
79. A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (**AMPLITUDE**)

80. A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (**ACIS**)
81. A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (**ARCHES**)
82. **ARMOR3-SV**: A phase III, randomized, open label, multicenter, controlled study of Galeterone compared to enzalutamide in men expressing androgen receptor splice variant-7 mRNA (AR-V7) metastatic castrate resistant prostate cancer (CRPC)
83. Letrozole for Estrogen/Progesterone Receptor positive low-grade Epithelial ovarian cancer. A randomized phase III trial. (**LEPRE Trial**)
84. Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (**MK-3475-564/KEYNOTE-564**)
85. A single arm, multicenter, international trial of tisotumab vedotin (HuMax®-TF-ADC) in previously treated, recurrent or metastatic cervical cancer
86. Phase IIIb randomized trial comparing irradiation plus long-term adjuvant androgen deprivation with GnRH antagonist versus GnRH agonist plus flare protection in patients with very high risk localized or locally advanced prostate cancer
87. A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (**LEAP-001**)
88. A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
89. A phase III, randomized, double-blind, placebo-controlled, multicenter trial testing ipatasertib plus abiraterone plus prednisone/prednisolone, relative to placebo plus abiraterone plus prednisone/prednisolone in adult male patients with asymptomatic or mildly symptomatic, previously untreated, metastatic castrate-resistant prostate cancer (**CO39303**)
90. A randomized, double-blind, phase 3 comparison of platinum-based therapy with tsr-042 and niraparib versus standard of care platinum-based therapy as first-line treatment of stage iii or iv nonmucinous epithelial ovarian cancer (**FIRST**)
91. An open label, single arm, multicenter safety study of atezolizumab in locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract (**SAUL**)
92. An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (**EV-301**)
93. An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer (**EV-302**)
94. Phase III randomized trial comparing irradiation plus long term adjuvant androgen suppression with LHRH antagonist versus LHRH agonist plus flare protection in patients with very high risk localized or locally advanced prostate cancer. A joint study of the EORTC ROG and GUCC (**PEGASUS**)
95. A prospective randomised phase III study of androgen deprivation therapy with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate cancer. (**PEACE I**)
96. A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. (**PEACE III**)
97. Studio di fase 4, randomizzato, in doppio cieco, controllato con placebo teso a valutare il trattamento continuato con enzalutamide in seguito alla progressione in pazienti affetti da cancro della prostata metastatico resistente alla castrazione e non trattati in precedenza con chemioterapia (**PLATO**)
98. A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy (**PREVAIL**)
99. Sviluppo del test PRIME per l'identificazione di biomarcatori tramite biopsia liquida (non

- invasiva) in pazienti con tumore alla prostata (studio biologico **PRIME**).
100. Studio clinico di fase 3, in aperto, randomizzato su regn2810 rispetto alla terapia chemioterapica scelta dallo sperimentatore nel carcinoma della cervice ricorrente o metastatico (**R2810-ONC-1676**)
 101. A phase 2 study of cemiplimab, an anti-pd-1 monoclonal antibody, and isa101b vaccine in patients with recurrent/metastatic hpv16 cervical cancer who have experienced disease progression after first line chemotherapy (**R2810-ONC-ISA-1981**)
 102. Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC) (**RAPSON**)
 103. Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen (**SGNTV-002**)
 104. A phase Ib/II study of GDC-068 or GDC-0980 with abiraterone acetate versus abiraterone acetate in patients with castration-resistant prostate4 cancer previously treated with docetaxel-based chemotherapy (**GO27983**)
 105. A Single arm, Multicenter, Phase 2b Trial Investigating the Efficacy of Tisotumab Vedotin (HuMax® TF ADC) Therapy in Previously treated Patients with Recurrent or Metastatic Cervical Cancer (**GCT1015-04**)
 106. A phase 2, open-label, response rate study of talazoparib in men with dna repair defects and metastatic castration-resistant prostate cancer who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal agent (enzalutamide and/or abiraterone acetate/prednisone) (**TALAPRO-1**)
 107. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib WITH ENZALUTAMIDE in Metastatic Castration-Resistant Prostate Cancer (**TALAPRO-2**)
 108. **TALAPRO-3**: A phase 3, randomized, double-blind, study of talazoparib with enzalutamide versus placebo with enzalutamide in men with ddr gene mutated metastatic castration-sensitive prostate cancer
 109. Cabazitaxel as salvage treatment for cisplatin-resistant germ cell cancer (**TestisCAB**)
 110. A phase III, open-label, multicenter, randomized study of atezolizumab (anti-pd-l1 antibody) versus observation as adjuvant therapy in patients with pd-l1–selected, high-risk muscle-invasive bladder cancer after cystectomy (**WO29636**)
 111. A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (anti-pd-l1 antibody) in combination with gemcitabine/carboplatin versus gemcitabine/carboplatin alone in patients with untreated locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-based therapy (**WO30070**)
 112. A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (anti-pd-l1 antibody) as adjuvant therapy in patients with renal cell carcinoma at high risk of developing metastasis following nephrectomy (**WO39210**)
 113. A phase III, multicenter, randomized, open-label study to evaluate the efficacy and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in patients with inoperable, locally advanced, or metastatic renal cell carcinoma who experienced radiographic tumor progression during or after immune checkpoint inhibitor treatment (**WO41994**)
 114. A phase II study evaluating the efficacy of enzalutamide and the role of ARv7 in metastatic castration resistant prostate cancer (mCRPC) patients with visceral disease. (**EXCALIBUR**)
 115. Studio in aperto, multicentrico, a due bracci, di fase 2 per determinare l'efficacia e la sicurezza di due diversi regimi di dosaggio di JNJ-42756493, un pan-inibitore della tirosin-chinasi FGFR, in soggetti con carcinoma uroteliale metastatico o non asportabile chirurgicamente con alterazioni genomiche dell'FGFR.(**42756493BLC2001 - J&J**)
 116. **MEET-URO 4** Studio multicentrico randomizzato di fase III: docetaxel vs ormonoterapia come trattamento di seconda linea in pazienti asintomatici o oligosintomatici con tumore della prostata metastatico, resistente alla castrazione, in progressione dopo terapia con abiraterone o enzalutamide.
 117. A Phase II, Randomized, Trial of Niraparib Versus Best Supportive Care as Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion Of First-line Platinum-containing Chemotherapy (**MEET-URO 12**)
 118. An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After 1 Prior Anti-PD-1/L1 Combination Regimen (**MK-**

6482-011)

119. Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) plus Pembrolizumab (MK-3475) Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (6482-022) (**MK-6482-022**)
120. A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (**MK7339-010**)
121. A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (**MK3475-641 / KEYNOTE-641**)
122. A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician's Choice in Participants with Advanced Endometrial Cancer (**MK3475-775**)
123. A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991) (**MK-3475-991**)
124. A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15) (**MK3475-C93**)
125. Nivolumab in combinazione con radioterapia stereotassica come trattamento di seconda e terza linea dei pazienti affetti da carcinoma renale metastatico (**NIVES**)
126. A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (**CA017-078**)
127. Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with FGFR3 Genomic Alterations (**PROOF-302**)
128. A Multinational Phase 3, Randomized, Open-label, Parallel group Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (**HERO**)
129. A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer. (**CA209-901**)
130. A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Have Received Prior Systemic Therapy (**CA209-67T**)
131. A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (**COSMIC-313**)
132. Studio di fase 2 in aperto con Cabozantinib in pazienti affetti da carcinoma renale avanzato o metastatico pretrattati con una linea di trattamento con inibitore degli immunocHECKPOints (anti PD1/PDL1): studio **BREAKPOINT**.
133. A Phase 2, randomized, non-comparative, open-label study of NKTR-214 in combination with nivolumab and of chemotherapy in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients with low PD L1 expression (**PIVOT-10**)
134. A Phase 2 study of INCMGA00012 (PD-1 inhibitor) in participants with selected solid tumors (**POD1UM-203**)
135. An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (**POD1UM-204**)
136. A Phase 2, Multicenter, Randomized, Single-Blind, Active-Control Study to Evaluate the Efficacy and Safety of Nivolumab Administered in Combination with IPI-549 Compared to Nivolumab Monotherapy in the Treatment of Patients with Immune Therapy-Naïve, Advanced Urothelial Carcinoma (**MARIO-275**)

137. A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3K α Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer (**C31004**)
138. A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy (**C31005**)
139. A phase III, double-blind, multicenter, randomized study of atezolizumab (anti-PD L1 antibody) versus placebo as adjuvant therapy in patients with high risk muscle invasive bladder cancer who are ctdna-positive following cystectomy (**BO42843**)
140. A multicentre phase III randomized study with second line chemotherapy plus or minus bevacizumab in patients with platinum sensitive epithelial ovarian cancer recurrence after a bevacizumab/chemotherapy first line" (**MITO 16B**)
141. Randomized phase III trial on Niraparib-TSR 042 vs physician's choice chemotherapy in recurrent, ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment: **MITO 33** trial
142. A phase II clinical trial of Pembrolizumab in combination with Carboplatin-Paclitaxel in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and fallopian tube cancer (**MITO 28**)
143. A randomized phase II trial of Carboplatin+Paclitaxel compared to Carboplatin+Paclitaxel+Avelumab in advanced (stage III-IV) or recurrent endometrial cancer (**MITO END 3**)
144. A multicenter study in patients with stage iii-iv epithelial ovarian cancer treated with carboplatin/paclitaxel with bevacizumab clinical and biological prognostic factors (**MITO16-MANGO-OV2-FASE IV**)
145. A randomized, molecular driven phase II trial of Carboplatin-PaclitaxelBevacizumab vs Carboplatin-PaclitaxelBevacizumab-Rucaparib vs Carboplatin-PaclitaxelRucaparib, selected according to HRD status, in patients with advanced (stage III B-C-IV) (**MITO 25.1**)
146. Studio clinico di fase 2 di Olaparib in pazienti affette da recidiva platino sensibile di carcinoma ovarico wild type per mutazione somatico o germinale dei geni BRCA1 e 2: studio traslazionale **MITO-31**
147. **MITO 35a**: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, primitive peritoneal, and fallopian tube cancer
148. Olaparib beyond progression compared to platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer patients. The phase III randomized, open label **MITO 35b** study: a project of the MITO-MANGO groups
149. A randomised double-blind, placebo-controlled phase III trial of maintenance Selnexor/placebo after combination chemotherapy for patients with advanced or recurrent endometrial cancer (**SIENDO**)
150. A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent or Recurrent Carcinoma of the Cervix (**BEATcc**)
151. Agnostic therapy in a phase II, multicenter, single-arm study in first-line treatment of durvalumab (medi 4736) in association with carboplatin or cisplatin and etoposide in patients affected by extensive stage - extrapulmonary small cell carcinoma (EPSCC) - **DURVASCC** trial
152. A phase 3, randomized, open-label, controlled study of cabozantinib (xl184) in combination with atezolizumab vs second novel hormonal therapy (nht) in subjects with metastatic castration.resistant prostate cancer (**CONTACT-02**)
153. Studio randomizzato di fase III in aperto che valuta sacituzumab govitecan rispetto al trattamento di scelta del medico in soggetti con carcinoma uroteliale non resecabile metastatico o localmente avanzato (**IMMU-132-13 - TROPICS-04**)
154. **ROSY-D**: A Master, Roll Over StudY for Patients Who Have Completed a Previous Oncology Study and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
155. A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Savolitinib plus Durvalumab versus Durvalumab in Participants with MET Driven, Unresectable and Locally Advanced, or Metastatic Papillary Renal Cell Carcinoma (PRCC) (**SAMETA**)
156. An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies

(STRONG)

157. A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (**VOLGA**)
158. Valutazione di fase 1/2a/3 della sicurezza ed efficacia dell'aggiunta di AL3818 (Anlotinib, INN: Catequentinib), un inibitore delle tirosin chinasi a doppio recettore, alla chemioterapia standard a base di platino in soggetti con carcinoma ricorrente o metastatico endometriale, ovarico, delle tube di Falloppio, peritoneale primario o cervicale. (**AL3818-US-002**)
159. Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors (**SGNLVA-005**)
160. A phase Ib/II study of GDC-068 or GDC-0980 with abiraterone acetate versus abiraterone acetate in patients with castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy (**GO27983**)
161. A phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC) (**CYCLONE-3**)
162. The **ROME** trial from histology to target: the road to personalize target therapy and immunotherapy
163. Uso terapeutico di Avelumab come mantenimento nei pazienti affetti da carcinoma uroteliale metastatico o localmente avanzato dopo la prima linea di trattamento chemioterapico a base di platino (**UT AVELUMAB VESCICA**)
164. Uso terapeutico di erdafitinib in pazienti affetti da carcinoma uroteliale avanzato FGFR mutato
165. Protocollo **AG41682** per l'accesso posttrial in regime di uso terapeutico con atezolizumab (Tecentriq®) in monoterapia
166. Phase II, exploratory, multicenter, non randomized, single agent cohort study to determine best tumor response with trastuzumab emtansine in HER2 overexpressing solid tumors (**KAMELEON – MO29694**)
167. A phase I, randomized, multicenter, open-label, controlled study of RO7247669 alone or in combination with tiragolumab versus atezolizumab in patients with previously untreated locally advanced or metastatic urothelial bladder cancer who are ineligible for platinum-containing chemotherapy (**BO44157**)
168. A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer. **IMMU-132-06 (TROPHY 01)**
169. A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress with First Line Platinum-Containing Chemotherapy (**JAVELIN Bladder Medley**)
170. Post trial **THOR_42756493BLC4012**
171. A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (**STELLAR 304 – XL092-304**)
172. Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor (**TINivo2**)
173. Therapeutic program guidance document for the use of Nivolumab in combination with Ipilimumab for the first line treatment of patients with intermediate and poor risk advanced or metastatic renal cell carcinoma (**UT Nivolumab + Ipilimumab**)
174. A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician's Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (**EvoPAR-Prostate01**)
175. **REJOICE-PanTumor01**: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants with Advanced/Metastatic Solid Tumors

Autorizzo l'utilizzo dei miei dati personali in accordo con il decreto legislativo 196/2003 e con il Regolamento Europeo 679/2016 - GDPR - sul trattamento dei dati personali.

Consapevole che le dichiarazioni false comportano l'applicazione delle sanzioni previste dall'art. 76 del D.P.R. 445/2000, dichiaro che le informazioni riportate nel curriculum vitae corrispondono a verità.